JCXH-105

BIOLOGICAL2 trials

Sponsors

Immorna Biotherapeutics, Inc.

Conditions

Herpes Zoster (HZ)Infectious DiseaseInfectious DiseasesShingles

Phase 1

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

CompletedNCT05871541

Immorna Biotherapeutics, Inc.Herpes Zoster (HZ), Infectious Disease, Shingles

Start: 2023-05-26End: 2024-03-25Updated: 2024-09-19

Phase 2

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Active, not recruitingNCT06581575

Immorna Biotherapeutics, Inc.Herpes Zoster (HZ), Infectious Diseases, Shingles

Start: 2024-10-16End: 2026-08-01Updated: 2026-04-23